131I-omburtamab
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for 131I-omburtamab, covering 2024-02-13 to 2026-02-05. Get the full timeline:
Most recent: Clinical Trial Update: 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma [Phase 2]